2006年至2020年间确诊的炎症性肠病患者皮质类固醇处方累积剂量:一项回顾性观察研究。

IF 4.3 3区 材料科学 Q1 ENGINEERING, ELECTRICAL & ELECTRONIC
ACS Applied Electronic Materials Pub Date : 2024-10-13 eCollection Date: 2024-01-01 DOI:10.1177/17562848241288851
Johannes Iiristo, Pontus Karling
{"title":"2006年至2020年间确诊的炎症性肠病患者皮质类固醇处方累积剂量:一项回顾性观察研究。","authors":"Johannes Iiristo, Pontus Karling","doi":"10.1177/17562848241288851","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Treatments and strategies for inflammatory bowel disease (IBD) have gradually evolved in the 2000s.</p><p><strong>Objectives: </strong>We investigated whether the prescription of corticosteroids (prednisolone and budesonide) in patients with IBD in the first 5 years after diagnosis changed in patients diagnosed between 2006 and 2018.</p><p><strong>Design: </strong>Retrospective observational study.</p><p><strong>Methods: </strong>The cumulative prescribed dosage of corticosteroids for the first 5 years after diagnosis was registered in all patients with IBD (<i>n</i> = 386) at our clinic for those diagnosed between 2006 and 2018.</p><p><strong>Results: </strong>The proportion of patients with IBD who were prescribed at least one prescription of corticosteroids in year 1-5 after diagnosis was 55.3%, 27.9%, 22.7%, 14.1%, and 14.6%, respectively. The proportion of patients who had a cumulative dose of prednisolone >1 g in the first 5 years after diagnosis was 40.1% for ulcerative colitis and 34.9% for Crohn's disease (CD). The cumulative prescribed dosage (within 3 years after diagnosis) of prednisolone had declined (rs = -0.164, <i>p</i> = 001), but had increased for budesonide (rs = 0.202, <i>p</i> < 0.001) between 2006 and 2020. The prescription of any immunomodulator for IBD in the first 5 years from diagnosis was stable between 2006 and 2018 (rs = 0.056, <i>p</i> = 0.257), but there was a minor increase in the prescription of Tumor Necrosis Factor (TNF)-inhibitors (rs = 0.119, <i>p</i> = 0.020). The use of five-acetyl salicylic acid (5-ASA) decreased in patients with CD (rs = -201, <i>p</i> = 0.012).</p><p><strong>Conclusion: </strong>There was a decrease in the prescription of prednisolone and an increase in the prescription of budesonide treatment from 2006 to 2023; however, the cumulative exposure to corticosteroids in patients with IBD remains at a relatively high level.</p>","PeriodicalId":3,"journal":{"name":"ACS Applied Electronic Materials","volume":null,"pages":null},"PeriodicalIF":4.3000,"publicationDate":"2024-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11472373/pdf/","citationCount":"0","resultStr":"{\"title\":\"Prescribed cumulative dosage of corticosteroids to patients with inflammatory bowel disease diagnosed between 2006 and 2020: a retrospective observational study.\",\"authors\":\"Johannes Iiristo, Pontus Karling\",\"doi\":\"10.1177/17562848241288851\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Treatments and strategies for inflammatory bowel disease (IBD) have gradually evolved in the 2000s.</p><p><strong>Objectives: </strong>We investigated whether the prescription of corticosteroids (prednisolone and budesonide) in patients with IBD in the first 5 years after diagnosis changed in patients diagnosed between 2006 and 2018.</p><p><strong>Design: </strong>Retrospective observational study.</p><p><strong>Methods: </strong>The cumulative prescribed dosage of corticosteroids for the first 5 years after diagnosis was registered in all patients with IBD (<i>n</i> = 386) at our clinic for those diagnosed between 2006 and 2018.</p><p><strong>Results: </strong>The proportion of patients with IBD who were prescribed at least one prescription of corticosteroids in year 1-5 after diagnosis was 55.3%, 27.9%, 22.7%, 14.1%, and 14.6%, respectively. The proportion of patients who had a cumulative dose of prednisolone >1 g in the first 5 years after diagnosis was 40.1% for ulcerative colitis and 34.9% for Crohn's disease (CD). The cumulative prescribed dosage (within 3 years after diagnosis) of prednisolone had declined (rs = -0.164, <i>p</i> = 001), but had increased for budesonide (rs = 0.202, <i>p</i> < 0.001) between 2006 and 2020. The prescription of any immunomodulator for IBD in the first 5 years from diagnosis was stable between 2006 and 2018 (rs = 0.056, <i>p</i> = 0.257), but there was a minor increase in the prescription of Tumor Necrosis Factor (TNF)-inhibitors (rs = 0.119, <i>p</i> = 0.020). The use of five-acetyl salicylic acid (5-ASA) decreased in patients with CD (rs = -201, <i>p</i> = 0.012).</p><p><strong>Conclusion: </strong>There was a decrease in the prescription of prednisolone and an increase in the prescription of budesonide treatment from 2006 to 2023; however, the cumulative exposure to corticosteroids in patients with IBD remains at a relatively high level.</p>\",\"PeriodicalId\":3,\"journal\":{\"name\":\"ACS Applied Electronic Materials\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":4.3000,\"publicationDate\":\"2024-10-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11472373/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ACS Applied Electronic Materials\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/17562848241288851\",\"RegionNum\":3,\"RegionCategory\":\"材料科学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q1\",\"JCRName\":\"ENGINEERING, ELECTRICAL & ELECTRONIC\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Electronic Materials","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/17562848241288851","RegionNum":3,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"ENGINEERING, ELECTRICAL & ELECTRONIC","Score":null,"Total":0}
引用次数: 0

摘要

背景:炎症性肠病(IBD)的治疗方法和策略在2000年代逐渐演变:我们调查了2006年至2018年期间确诊的IBD患者在确诊后头5年中皮质类固醇(泼尼松龙和布地奈德)的处方是否发生了变化:回顾性观察研究:对我院2006年至2018年间确诊的所有IBD患者(n=386)确诊后前5年皮质类固醇的累计处方剂量进行登记:确诊后第1-5年至少使用过一次皮质类固醇的IBD患者比例分别为55.3%、27.9%、22.7%、14.1%和14.6%。溃疡性结肠炎和克罗恩病(CD)患者在确诊后前 5 年内泼尼松龙累计剂量大于 1 克的比例分别为 40.1%和 34.9%。泼尼松龙的累计处方剂量(确诊后 3 年内)有所下降(rs = -0.164,p = 001),但布地奈德的处方剂量有所增加(rs = 0.202,p = 0.257),但肿瘤坏死因子 (TNF) 抑制剂的处方剂量略有增加(rs = 0.119,p = 0.020)。CD患者使用五乙酰水杨酸(5-ASA)的情况有所减少(rs = -201,p = 0.012):结论:从 2006 年到 2023 年,泼尼松龙的处方量有所减少,布地奈德的处方量有所增加;然而,IBD 患者皮质类固醇的累积暴露量仍处于相对较高的水平。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Prescribed cumulative dosage of corticosteroids to patients with inflammatory bowel disease diagnosed between 2006 and 2020: a retrospective observational study.

Background: Treatments and strategies for inflammatory bowel disease (IBD) have gradually evolved in the 2000s.

Objectives: We investigated whether the prescription of corticosteroids (prednisolone and budesonide) in patients with IBD in the first 5 years after diagnosis changed in patients diagnosed between 2006 and 2018.

Design: Retrospective observational study.

Methods: The cumulative prescribed dosage of corticosteroids for the first 5 years after diagnosis was registered in all patients with IBD (n = 386) at our clinic for those diagnosed between 2006 and 2018.

Results: The proportion of patients with IBD who were prescribed at least one prescription of corticosteroids in year 1-5 after diagnosis was 55.3%, 27.9%, 22.7%, 14.1%, and 14.6%, respectively. The proportion of patients who had a cumulative dose of prednisolone >1 g in the first 5 years after diagnosis was 40.1% for ulcerative colitis and 34.9% for Crohn's disease (CD). The cumulative prescribed dosage (within 3 years after diagnosis) of prednisolone had declined (rs = -0.164, p = 001), but had increased for budesonide (rs = 0.202, p < 0.001) between 2006 and 2020. The prescription of any immunomodulator for IBD in the first 5 years from diagnosis was stable between 2006 and 2018 (rs = 0.056, p = 0.257), but there was a minor increase in the prescription of Tumor Necrosis Factor (TNF)-inhibitors (rs = 0.119, p = 0.020). The use of five-acetyl salicylic acid (5-ASA) decreased in patients with CD (rs = -201, p = 0.012).

Conclusion: There was a decrease in the prescription of prednisolone and an increase in the prescription of budesonide treatment from 2006 to 2023; however, the cumulative exposure to corticosteroids in patients with IBD remains at a relatively high level.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
7.20
自引率
4.30%
发文量
567
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信